Related Experiment Video
Updated: May 3, 2026

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
Published on: July 18, 2016
Fluorescence-lifetime molecular imaging can detect invisible peritoneal ovarian tumors in bloody ascites
Takahito Nakajima1, Kohei Sano, Kazuhide Sato
1Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MA, USA.
Abstract:
Blood contamination, such as bloody ascites or hemorrhages during surgery, is a potential hazard for clinical application of fluorescence imaging. In order to overcome this problem, we investigate if fluorescence-lifetime imaging helps to overcome this problem. Samples were prepared at concentrations ranging 0.3-2.4 μm and mixed with 0-10% of blood. Fluorescence intensities and lifetimes of samples were measured using a time-domain fluorescence imager. Ovarian cancer SHIN3 cells overexpressing the D-galactose receptor were injected into the peritoneal cavity 2.5 weeks before the experiments. Galactosyl serum albumin-rhodamine green (GSA-RhodG), which bound to the D-galactose receptor and was internalized thereafter, was administered intraperitoneally to peritoneal ovarian cancer-bearing mice with various degrees of bloody ascites. In vitro study showed a linear correlation between fluorescence intensity and probe concentration (r(2) > 0.99), whereas the fluorescence lifetime was consistent (range, 3.33 ± 0.15-3.75 ± 0.04 ns). By adding 10% of blood to samples, fluorescence intensities decreased to <1%, while fluorescence lifetimes were consistent. In vivo fluorescence lifetime of GSA-RhodG stained tumors was longer than the autofluorescence lifetime (threshold, 2.87 ns). Tumor lesions under hemorrhagic peritonitis were not depicted using fluorescence intensity imaging; however, fluorescence-lifetime imaging clearly detected tumor lesions by prolonged lifetimes. In conclusion, fluorescence-lifetime imaging with GSA-RhodG depicted ovarian cancer lesions, which were invisible in intensity images, in hemorrhagic ascites.
Insights
Fluorescence-lifetime imaging overcomes blood contamination issues in detecting ovarian cancer. This technique clearly visualizes tumor lesions in bloody ascites, which are invisible with standard fluorescence intensity imaging.
Area of Science:
- Biomedical Optics
- Medical Imaging
- Ovarian Cancer Research
Background:
- Clinical fluorescence imaging faces challenges due to blood contamination from ascites or surgical hemorrhages.
- Overcoming these limitations is crucial for accurate in vivo imaging and diagnosis.
Purpose of the Study:
- To investigate the efficacy of fluorescence-lifetime imaging (FLI) in overcoming blood contamination for ovarian cancer detection.
- To evaluate the performance of galactosyl serum albumin-rhodamine green (GSA-RhodG) in FLI of ovarian cancer in the presence of bloody ascites.
Main Methods:
- In vitro and in vivo experiments using ovarian cancer models (SHIN3 cells) in mice with induced bloody ascites.
- Measurements of fluorescence intensity and lifetime using a time-domain fluorescence imager.
- Administration of GSA-RhodG probe targeting D-galactose receptors on cancer cells.
Main Results:
- In vitro, fluorescence intensity correlated linearly with probe concentration, while lifetime remained stable.
- Addition of blood (up to 10%) significantly reduced fluorescence intensity (<1%) but did not affect fluorescence lifetime.
- In vivo, FLI successfully detected tumor lesions in hemorrhagic ascites, whereas intensity imaging failed.
Conclusions:
- Fluorescence-lifetime imaging with GSA-RhodG provides robust detection of ovarian cancer lesions even in the presence of significant blood contamination.
- FLI offers a promising solution to overcome the limitations of intensity-based fluorescence imaging in clinically relevant scenarios.

